

# Armand Bensussan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2590499/publications.pdf>

Version: 2024-02-01

234  
papers

10,152  
citations

36303

51  
h-index

46799

89  
g-index

268  
all docs

268  
docs citations

268  
times ranked

11516  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutting Edge: Soluble HLA-G1 Triggers CD95/CD95 Ligand-Mediated Apoptosis in Activated CD8+ Cells by Interacting with CD8. <i>Journal of Immunology</i> , 2000, 164, 6100-6104.	0.8	422
2	Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1209-1215.	2.9	353
3	Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. <i>Cell Reports</i> , 2019, 27, 2411-2425.e9.	6.4	274
4	Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2002, 118, 728-733.	0.7	260
5	IL-10 produced by activated human B cells regulates CD4 <sup>+</sup> T cell activation <i>in vitro</i> . <i>European Journal of Immunology</i> , 2010, 40, 2686-2691.	2.9	216
6	IFN- $\gamma$ kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5294-5299.	7.1	205
7	VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2837-2842.	7.1	193
8	Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity. <i>Cancer Immunology Research</i> , 2015, 3, 254-265.	3.4	190
9	Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. <i>Blood</i> , 2006, 108, 2608-2615.	1.4	181
10	Biological Activity of Soluble CD100. II. Soluble CD100, Similarly to H-SemaIII, Inhibits Immune Cell Migration. <i>Journal of Immunology</i> , 2001, 166, 4348-4354.	0.8	154
11	CD39/Adenosine Pathway Is Involved in AIDS Progression. <i>PLoS Pathogens</i> , 2011, 7, e1002110.	4.7	154
12	Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. <i>European Journal of Immunology</i> , 1997, 27, 3380-3388.	2.9	152
13	Evaluation of the Potential Role of Cytokines in Toxic Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2004, 123, 850-855.	0.7	152
14	CD24 <sup>hi</sup> CD27 <sup>+</sup> and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 1830-1839.	1.4	144
15	The Uterine Immune Profile May Help Women With Repeated Unexplained Embryo Implantation Failure After <i>In Vitro</i> Fertilization. <i>American Journal of Reproductive Immunology</i> , 2016, 75, 388-401.	1.2	143
16	CD158k/KIR3DL2 Is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-Up of Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2004, 122, 820-823.	0.7	135
17	Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis. <i>Journal of Immunology</i> , 2001, 166, 4341-4347.	0.8	130
18	Isolation of Tumor-Specific Cytotoxic CD4 <sup>+</sup> and CD4 <sup>+</sup> CD8 <sup>dim</sup> <sup>+</sup> T-Cell Clones Infiltrating a Cutaneous T-Cell Lymphoma. <i>Blood</i> , 1998, 91, 4331-4341.	1.4	128

#	ARTICLE	IF	CITATIONS
19	Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16963-16968.	7.1	128
20	Critical and Differential Roles of NKp46- and NKp30-Activating Receptors Expressed by Uterine NK Cells in Early Pregnancy. Journal of Immunology, 2008, 181, 3009-3017.	0.8	125
21	CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. Journal of Immunology, 2015, 195, 4555-4563.	0.8	125
22	T Cell Receptor (TCR) Interacting Molecule (TRIM), A Novel Disulfide-linked Dimer Associated with the TCR-CD3- $\zeta$ Complex, Recruits Intracellular Signaling Proteins to the Plasma Membrane. Journal of Experimental Medicine, 1998, 188, 561-575.	8.5	121
23	CD4+ cutaneous T-cell lymphoma cells express the p140 killer cell immunoglobulin-like receptor. Blood, 2001, 97, 1388-1391.	1.4	119
24	IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Scientific Reports, 2013, 3, 3456.	3.3	119
25	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncology, The, 2019, 20, 1160-1170.	10.7	119
26	Interferon: a cytotoxic T lymphocyte differentiation signal. European Journal of Immunology, 1986, 16, 767-770.	2.9	113
27	Soluble CD14 acts as a negative regulator of human T cell activation and function. European Journal of Immunology, 1999, 29, 265-276.	2.9	111
28	CD molecules 2005: human cell differentiation molecules. Blood, 2005, 106, 3123-3126.	1.4	110
29	Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2891-2896.	7.1	107
30	Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset. Journal of Immunology, 2004, 173, 5349-5354.	0.8	105
31	Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. International Journal of Molecular Sciences, 2016, 17, 1433.	4.1	104
32	Semaphorin CD100 from Activated T Lymphocytes Induces Process Extension Collapse in Oligodendrocytes and Death of Immature Neural Cells. Journal of Immunology, 2004, 172, 1246-1255.	0.8	97
33	BY55/CD160 acts as a coreceptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. International Immunology, 2002, 14, 445-451.	4.0	88
34	Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. International Immunology, 2005, 17, 439-447.	4.0	84
35	A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood, 2010, 116, 1637-1647.	1.4	83
36	Clonotypic Surface Structure on Human T Lymphocytes: Functional and Biochemical Analysis of the Antigen Receptor Complex. Immunological Reviews, 1984, 81, 95-130.	6.0	82

#	ARTICLE	IF	CITATIONS
37	ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 584-591.	8.2	81
38	CD160: A unique activating NK cell receptor. <i>Immunology Letters</i> , 2011, 138, 93-96.	2.5	81
39	Cutaneous T Cell Lymphoma Reactive CD4+ Cytotoxic T Lymphocyte Clones Display a Th1 Cytokine Profile and Use a Fas-Independent Pathway for Specific Tumor Cell Lysis. <i>Journal of Investigative Dermatology</i> , 2000, 115, 74-80.	0.7	80
40	Regulatory T-Cells in Pregnancy: Historical Perspective, State of the Art, and Burning Questions. <i>Frontiers in Immunology</i> , 2014, 5, 389.	4.8	79
41	Evaluation of Immunophenotypic and Molecular Biomarkers for SÅ©zary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1364-1372.	0.7	78
42	Active Chronic Sarcoidosis is Characterized by Increased Transitional Blood B Cells, Increased IL-10-Producing Regulatory B Cells and High BAFF Levels. <i>PLoS ONE</i> , 2012, 7, e43588.	2.5	78
43	Significance of circulating T-cell clones in Sezary syndrome. <i>Blood</i> , 2006, 107, 4030-4038.	1.4	69
44	IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma. <i>Cancer Research</i> , 2014, 74, 6060-6070.	0.9	65
45	SC5 mAb Represents a Unique Tool for the Detection of Extracellular Vimentin as a Specific Marker of Sezary Cells. <i>Journal of Immunology</i> , 2006, 176, 652-659.	0.8	63
46	Activation signals are delivered through two distinct epitopes of CD100, a unique 150 kDa human lymphocyte surface structure previously defined by BB18 mAb. <i>International Immunology</i> , 1995, 7, 1-8.	4.0	61
47	Identification and Characterization of a Transmembrane Isoform of CD160 (CD160-TM), a Unique Activating Receptor Selectively Expressed upon Human NK Cell Activation. <i>Journal of Immunology</i> , 2009, 182, 63-71.	0.8	58
48	CD158k Is a Reliable Marker for Diagnosis of SÅ©zary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells. <i>Journal of Investigative Dermatology</i> , 2015, 135, 247-257.	0.7	56
49	<i>PARKIN</i> Inactivation Links Parkinson's Disease to Melanoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv340.	6.3	56
50	The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. <i>European Journal of Immunology</i> , 2006, 36, 2359-2366.	2.9	55
51	The Human Semaphorin-like Leukocyte Cell Surface Molecule CD100 Associates with a Serine Kinase Activity. <i>Journal of Biological Chemistry</i> , 1997, 272, 23515-23520.	3.4	54
52	Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets. <i>Blood</i> , 2009, 113, 4556-4565.	1.4	54
53	TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. <i>Oncotarget</i> , 2016, 7, 53127-53136.	1.8	54
54	Granulocyte-Colony Stimulating Factor Related Pathways Tested on an Endometrial Ex-Vivo Model. <i>PLoS ONE</i> , 2014, 9, e102286.	2.5	53

#	ARTICLE	IF	CITATIONS
55	IFN- $\gamma$ and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18995-19000.	7.1	52
56	A Soluble Form of the MHC Class I-Specific CD160 Receptor Is Released from Human Activated NK Lymphocytes and Inhibits Cell-Mediated Cytotoxicity. <i>Journal of Immunology</i> , 2007, 178, 1293-1300.	0.8	51
57	CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of S $\alpha$ zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2008, 128, 465-472.	0.7	51
58	Histopathologic Diagnosis of Lymphomatous Versus Inflammatory Erythroderma: A Morphologic and Phenotypic Study on 47 Skin Biopsies. <i>American Journal of Dermatopathology</i> , 2010, 32, 755-763.	0.6	51
59	The Interleukin-17 Family of Cytokines in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3880.	4.1	50
60	T3-Ti receptor triggering of T8+ suppressor T cells leads to unresponsiveness to interleukin-2. <i>Nature</i> , 1984, 311, 565-567.	27.8	49
61	CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 3079-3088.	1.4	48
62	Killer cell immunoglobulin-like receptor expression delineates in situ S $\alpha$ zary syndrome lymphocytes. <i>Journal of Pathology</i> , 2003, 199, 77-83.	4.5	47
63	Differential and tumor-specific expression of CD160 in B-cell malignancies. <i>Blood</i> , 2011, 118, 2174-2183.	1.4	47
64	Uterine immune profiling for increasing live birth rate: A one-to-one matched cohort study. <i>Journal of Reproductive Immunology</i> , 2017, 119, 23-30.	1.9	47
65	Atypical BRAF and NRAS Mutations in Mucosal Melanoma. <i>Cancers</i> , 2019, 11, 1133.	3.7	47
66	Interferon- $\beta$ rescues HLA class Ia cell surface expression in term villous trophoblast cells by inducing synthesis of TAP proteins. <i>European Journal of Immunology</i> , 1997, 27, 45-54.	2.9	46
67	A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. <i>Journal of Experimental Medicine</i> , 2011, 208, 973-986.	8.5	46
68	Phenotypic and functional changes in dermal primary fibroblasts isolated from intrinsically aged human skin. <i>Experimental Dermatology</i> , 2016, 25, 113-119.	2.9	46
69	TCR $\beta$ Bearing T Lymphocytes Infiltrating Human Primary Cutaneous Melanomas. <i>Journal of Investigative Dermatology</i> , 1992, 98, 369-374.	0.7	45
70	IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. <i>Scientific Reports</i> , 2015, 5, 11874.	3.3	45
71	Soluble HLA-G and control of angiogenesis. <i>Journal of Reproductive Immunology</i> , 2007, 76, 17-22.	1.9	44
72	Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signalling pathways. <i>British Journal of Dermatology</i> , 2017, 177, 1322-1336.	1.5	44

#	ARTICLE	IF	CITATIONS
73	Circulating and skin-derived S <sup>Å</sup> zary cells: clonal but with phenotypic plasticity. <i>Blood</i> , 2017, 130, 1468-1471.	1.4	44
74	CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. <i>International Immunology</i> , 2007, 19, 401-409.	4.0	42
75	Expression and Function of the Natural Cytotoxicity Receptor NKp46 on Circulating Malignant CD4+ T Lymphocytes of S <sup>Å</sup> zary Syndrome Patients. <i>Journal of Investigative Dermatology</i> , 2011, 131, 969-976.	0.7	41
76	TWEAK Affects Keratinocyte G2/M Growth Arrest and Induces Apoptosis through the Translocation of the AIF Protein to the Nucleus. <i>PLoS ONE</i> , 2012, 7, e33609.	2.5	41
77	Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with S <sup>Å</sup> zary Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, 3619-3627.	7.0	41
78	The human T-cell receptor. <i>Journal of Clinical Immunology</i> , 1985, 5, 141-157.	3.8	39
79	Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. <i>Scientific Reports</i> , 2017, 7, 7201.	3.3	39
80	Circulating Natural Killer Lymphocytes Are Potential Cytotoxic Effectors Against Autologous Malignant Cells in Sezary Syndrome Patients. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1273-1278.	0.7	37
81	Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133. <i>Cancers</i> , 2011, 3, 2870-2885.	3.7	36
82	CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides. <i>Experimental Dermatology</i> , 2012, 21, 461-463.	2.9	36
83	Up-and-down immunity of pregnancy in humans. <i>F1000Research</i> , 2017, 6, 1216.	1.6	36
84	Impact of prednisone in patients with repeated embryo implantation failures: Beneficial or deleterious?. <i>Journal of Reproductive Immunology</i> , 2018, 127, 11-15.	1.9	36
85	Switch in the protein tyrosine phosphatase associated with human CD100 semaphorin at terminal B-cell differentiation stage. <i>Blood</i> , 2000, 95, 965-972.	1.4	36
86	Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production. <i>European Journal of Immunology</i> , 2000, 30, 3132-3139.	2.9	35
87	Structure and Function of the Immune Semaphorin CD100/SEMA4D. <i>Critical Reviews in Immunology</i> , 2003, 23, 65-81.	0.5	35
88	Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. <i>Experimental Dermatology</i> , 2011, 20, 107-112.	2.9	35
89	Heterogeneous Abnormalities of CCND1 and RB1 in Primary Cutaneous T-Cell Lymphomas Suggesting Impaired Cell Cycle Control in Disease Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1388-1395.	0.7	33
90	Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. <i>Blood</i> , 2012, 120, 143-154.	1.4	33

#	ARTICLE	IF	CITATIONS
91	CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression. <i>Oncolimmunology</i> , 2015, 4, e1003015.	4.6	33
92	Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside. <i>Journal of Reproductive Immunology</i> , 2015, 109, 1-6.	1.9	33
93	The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. <i>Oncotarget</i> , 2017, 8, 113360-113372.	1.8	33
94	Engagement of ILT2/CD85j in Sezary syndrome cells inhibits their CD3/TCR signaling. <i>Blood</i> , 2002, 100, 1019-1025.	1.4	31
95	Identification of a Novel CD160+CD4+ T-Lymphocyte Subset in the Skin: A Possible Role for CD160 in Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1161-1166.	0.7	31
96	The CD39 molecule defines distinct cytotoxic subsets within alloactivated human CD8-positive cells. <i>European Journal of Immunology</i> , 1992, 22, 2681-2685.	2.9	30
97	KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. <i>Blood</i> , 2017, 130, 2900-2902.	1.4	30
98	MDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN- $\beta$ Transcript. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1276-1279.e7.	0.7	30
99	Functional characterization of an IL-7 $\alpha$ -dependent CD4+CD8 $\alpha\beta$ + Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. <i>Blood</i> , 2000, 96, 1056-1063.	1.4	29
100	Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. <i>Oncolimmunology</i> , 2014, 3, e28273.	4.6	29
101	Production and characterization of antibody probes directed at constant regions of the $\epsilon$ and $\delta$ subunit of the human T cell receptor. <i>European Journal of Immunology</i> , 1985, 15, 821-827.	2.9	28
102	The CD160+ CD8 <sup>high</sup> cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients. <i>Cellular Immunology</i> , 2005, 237, 96-105.	3.0	28
103	Seminal plasma peptides may determine maternal immune response that alters success or failure of pregnancy in the abortion-prone CBAxDBA/2 model. <i>Journal of Reproductive Immunology</i> , 2013, 99, 46-53.	1.9	28
104	Increased Expression of a Novel Early Activation Surface Membrane Receptor in Cutaneous T Cell Lymphoma Cells. <i>Journal of Investigative Dermatology</i> , 2001, 116, 731-738.	0.7	27
105	Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition. <i>International Journal of Cancer</i> , 2015, 136, 2109-2119.	5.1	27
106	Do Primary Cutaneous Non-T Non-B CD4+CD56+ Lymphomas Belong to the Myelo-Monocytic Lineage?. <i>Journal of Investigative Dermatology</i> , 1998, 111, 1242-1244.	0.7	26
107	Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. <i>British Journal of Haematology</i> , 2014, 165, 722-725.	2.5	26
108	RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. <i>Oncotarget</i> , 2015, 6, 28120-28131.	1.8	26

#	ARTICLE	IF	CITATIONS
109	PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. <i>Oncogene</i> , 2017, 36, 3252-3262.	5.9	25
110	Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with SÅ©zary syndrome. <i>Blood</i> , 2007, 109, 5064-5065.	1.4	23
111	Human and Mouse Mast Cells Express and Secrete the GPI-Anchored Isoform of CD160. <i>Journal of Investigative Dermatology</i> , 2011, 131, 916-924.	0.7	23
112	Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. <i>Haematologica</i> , 2021, 106, 1193-1197.	3.5	23
113	IL-17E synergizes with EGF and confers <i>in vitro</i> resistance to EGFR-targeted therapies in TNBC cells. <i>Oncotarget</i> , 2016, 7, 53350-53361.	1.8	23
114	Activation of the CD3/T cell receptor (TcR) complex or of protein kinase C potentiate adenylyl cyclase stimulation in a tumoral T cell line: involvement of two distinct intracellular pathways. <i>European Journal of Immunology</i> , 1991, 21, 2877-2882.	2.9	22
115	Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma. <i>Oncogene</i> , 2003, 22, 7192-7198.	5.9	22
116	KIR3DL2 is a coinhibitory receptor on SÅ©zary syndrome malignant T cells that promotes resistance to activation-induced cell death. <i>Blood</i> , 2014, 124, 3330-3332.	1.4	22
117	Microenvironment tailors nTreg structure and function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6298-6307.	7.1	22
118	Control of allergic reactions in mice by an active anti-murine IL-4 immunization. <i>Vaccine</i> , 2007, 25, 7206-7216.	3.8	21
119	A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. <i>Oncolmmunology</i> , 2015, 4, e1022306.	4.6	21
120	HLA Class I/NK Cell Receptor Interaction in Early Human Decidua basalis: Possible Functional Consequences. , 2005, 89, 72-83.		20
121	Revisiting the initial diagnosis and blood staging of mycosis fungoides and SÅ©zary syndrome with the <sc>KIR</sc> 3 <sc>DL</sc> 2 marker. <i>British Journal of Dermatology</i> , 2020, 182, 1415-1422.	1.5	20
122	Differential proliferative responses in subsets of human CD28+cells delineated by BB27 mAb. <i>International Immunology</i> , 1994, 6, 423-430.	4.0	19
123	Antiproliferative Effect of Semaphorin 3F on Human Melanoma Cell Lines. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2343-2345.	0.7	19
124	Recent discoveries in the genetics of melanoma and their therapeutic implications. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2007, 55, 363-372.	2.3	19
125	Extranodal NK/T-Cell Lymphoma: Toward the Identification of Clinical Molecular Targets. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-11.	3.0	19
126	A Large French Case-Control Study Emphasizes the Role of Rare<i>Mc1R</i> Variants in Melanoma Risk. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	19



#	ARTICLE	IF	CITATIONS
127	Persistent deficiency of mucosal-associated invariant T cells during dermatomyositis. <i>Rheumatology</i> , 2020, 59, 2282-2286.	1.9	19
128	Proliferation of resting lymphocytes is induced by triggering T cells through an epitope common to the three CD18/CD11 leukocyte adhesion molecules. <i>Cellular Immunology</i> , 1991, 136, 519-524.	3.0	18
129	Functional Characterization of Neurotensin Receptors in Human Cutaneous T Cell Lymphoma Malignant Lymphocytes. <i>Journal of Investigative Dermatology</i> , 2001, 117, 687-693.	0.7	18
130	Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas. <i>Frontiers in Immunology</i> , 2017, 8, 1010.	4.8	18
131	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020, 4, 5203-5214.	5.2	18
132	Immunoactive products of human placenta. II. Direct inhibition of non-MHC restricted cytolytic activity of human CD3 alpha-beta but not CD3 gamma-delta expressing T cell clones. <i>Journal of Reproductive Immunology</i> , 1989, 16, 137-150.	1.9	17
133	Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects. <i>Journal of Dermatological Science</i> , 2011, 64, 127-133.	1.9	17
134	Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>JAMA Dermatology</i> , 2017, 153, 184.	4.1	17
135	Sezary Syndrome Cells Unlike Normal Circulating T Lymphocytes Fail to Migrate Following Engagement of NT1 Receptor. <i>Journal of Investigative Dermatology</i> , 2004, 122, 111-118.	0.7	16
136	NKG2D Ligands Expression and NKG2D-Mediated NK Activity in Sezary Patients. <i>Journal of Investigative Dermatology</i> , 2009, 129, 359-364.	0.7	16
137	CD101 Expression and Function in Normal and Rheumatoid Arthritis-affected Human T Cells and Monocytes/Macrophages. <i>Journal of Rheumatology</i> , 2011, 38, 419-428.	2.0	16
138	Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4 <sup>+</sup> T <sub>H</sub> 1 lymphocyte subset in normal and mycosis fungoides skin. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014, 85, 869-882.	1.5	16
139	Expression of S <sup>Å</sup> zary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2016, 136, 317-320.	0.7	16
140	Cutting Edge: Selective Expression of Inhibitory or Activating Killer Cell Ig-Like Receptors in Circulating CD4 <sup>+</sup> T Lymphocytes. <i>Journal of Immunology</i> , 2008, 180, 2767-2771.	0.8	15
141	T-Plastin Expression Downstream to the Calcineurin/NFAT Pathway Is Involved in Keratinocyte Migration. <i>PLoS ONE</i> , 2014, 9, e104700.	2.5	15
142	In vivo anti-MUC1 <sup>+</sup> tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1337-1352.	4.2	15
143	A Monoclonal Antibody to the Hodgkin's Disease-Associated Antigen CD30 Induces Activation and Long-Term Growth of Human Autoreactive T <sub>H</sub> 1 T Cell Clone. <i>Cellular Immunology</i> , 1994, 156, 230-239.	3.0	14
144	Engagement of the CD160 activating NK cell receptor leads to its association with CD2 in circulating human NK cells. <i>Transplant Immunology</i> , 2006, 17, 36-38.	1.2	14

#	ARTICLE	IF	CITATIONS
145	NK cells and surveillance in humans. <i>Reproductive BioMedicine Online</i> , 2008, 16, 192-201.	2.4	14
146	KIR3DL2/CpG ODN Interaction Mediates SÅ©zary Syndrome Malignant T Cell Apoptosis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 229-237.	0.7	14
147	Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. <i>Scientific Reports</i> , 2017, 7, 41125.	3.3	14
148	Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in SÅ©zary syndrome. <i>Blood</i> , 2022, 139, 2712-2716.	1.4	14
149	Increased Number of Cytotoxic CD3+CD28â€“Î³Î± T Cells in Peripheral Blood of Patients with Cutaneous Malignant Melanoma. <i>Dermatology</i> , 2007, 214, 283-288.	2.1	13
150	HACE1, a Potential Tumor Suppressor Gene on 6q21, Is Not Involved in Extranodal Natural Killer/T-Cell Lymphoma Pathophysiology. <i>American Journal of Pathology</i> , 2014, 184, 2899-2907.	3.8	13
151	Isolation of Tumor-Specific Cytotoxic CD4+ and CD4+CD8dim+ T-Cell Clones Infiltrating a Cutaneous T-Cell Lymphoma. <i>Blood</i> , 1998, 91, 4331-4341.	1.4	13
152	Correlation between T cell receptor Î³Î± isotypic forms and cytotoxic activity: Analysis with human T cell clones and lines. <i>Cellular Immunology</i> , 1990, 125, 315-325.	3.0	12
153	Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair. <i>Frontiers in Immunology</i> , 2017, 8, 1413.	4.8	12
154	Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit. <i>Stem Cells Translational Medicine</i> , 2019, 8, 911-924.	3.3	12
155	Immunodeficiency after Bone Marrow Transplantation can be associated with Autoreactive T-Cell Receptor gammaomega-bearing Lymphocytes. <i>Immunological Reviews</i> , 1990, 116, 5-13.	6.0	11
156	Deficient regulatory B cells in human chronic graft-versus-host disease. <i>OncolImmunology</i> , 2015, 4, e1016707.	4.6	11
157	MUC1-ARFâ€”A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA. <i>PLoS ONE</i> , 2016, 11, e0165031.	2.5	11
158	What is a T-cell clone? Effect of rIFN on T-cell clone function and T-cell receptor gene rearrangement. <i>Human Immunology</i> , 1986, 17, 214-223.	2.4	10
159	Selective induction of autocytotoxic activity through the CD3 molecule. <i>European Journal of Immunology</i> , 1990, 20, 2615-2619.	2.9	10
160	Evidence of <sc>T</sc>h1, <sc>T</sc>h17 and <sc>T</sc>c17 cells in psoriasiform chronic graftâ€versusâ€host disease. <i>Experimental Dermatology</i> , 2016, 25, 64-65.	2.9	10
161	Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016. <i>Annales De Dermatologie Et De Venereologie</i> , 2018, 145, 405-412.	1.0	10
162	Increased expression of <sc>PD</sc>1 and <sc>CD</sc>39 on <sc>CD</sc>3<sup>+</sup><sc>CD</sc>4<sup>+</sup> skin T cells in the elderly. <i>Experimental Dermatology</i> , 2019, 28, 80-82.	2.9	10

#	ARTICLE	IF	CITATIONS
163	Nucleotide sequence of a cDNA corresponding to a new human variable region of a functionally rearranged T cell receptor gamma chain. <i>Nucleic Acids Research</i> , 1987, 15, 10059-10059.	14.5	9
164	Functional Inhibitory Receptors Expressed by a Cutaneous T Cell Lymphoma-Specific Cytolytic Clonal T Cell Population. <i>Journal of Investigative Dermatology</i> , 2000, 115, 994-999.	0.7	9
165	Polymorphic expression of CD158k/p140/KIR3DL2 in Sezary patients. <i>Blood</i> , 2003, 101, 1203-1203.	1.4	9
166	Active and Passive Anticytokine Immune Therapies: Current Status and Development. <i>Advances in Immunology</i> , 2012, 115, 187-227.	2.2	9
167	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. <i>Haematologica</i> , 2016, 101, e312-e315.	3.5	9
168	Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results. <i>Hematological Oncology</i> , 2017, 35, 48-49.	1.7	8
169	Truncating mutations of <i>TP53AIP1</i> gene predispose to cutaneous melanoma. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 294-303.	2.8	8
170	Cytokine levels in persistent skin lesions of adult-onset Still disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 947-949.	1.2	8
171	Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape. <i>Cancer Management and Research</i> , 2018, Volume 10, 1051-1059.	1.9	8
172	Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4344-55.	0.5	8
173	Regulation of the human allogeneic proliferative response in vitro. <i>Immunogenetics</i> , 1981, 14, 117-127.	2.4	7
174	Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue. <i>International Immunology</i> , 2001, 13, 441-450.	4.0	7
175	CD Antigens 2001. <i>Modern Pathology</i> , 2002, 15, 71-76.	5.5	7
176	Immunopathogenesis of cutaneous T-cell lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1313-1317.	2.2	7
177	Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models. , 2018, 59, 2687.		7
178	The value of five blood markers in differentiating mycosis fungoides and S�azary syndrome: a validation cohort. <i>British Journal of Dermatology</i> , 2021, 185, 405-411.	1.5	7
179	Allospecific proliferative human T-cell clones acquire the cytotoxic effector function after three months in culture, in IL-2 conditioned medium. <i>Human Immunology</i> , 1986, 17, 30-36.	2.4	6
180	Trem� is not crucial in psoriasiform imiquimod�induced skin inflammation in mice. <i>Experimental Dermatology</i> , 2016, 25, 400-402.	2.9	6

#	ARTICLE	IF	CITATIONS
181	CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases. , 2018, 59, 2679.		6
182	Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of SÅ©zary Syndrome Patients. Journal of Investigative Dermatology, 2019, 139, 725-728.	0.7	6
183	Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial. Blood, 2018, 132, 1627-1627.	1.4	6
184	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. Blood, 2016, 128, 1826-1826.	1.4	6
185	CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. Blood Advances, 2022, 6, 3507-3512.	5.2	6
186	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 2731-2742.	4.2	6
187	Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes. Immunology Letters, 2011, 139, 52-57.	2.5	5
188	Genetic variation at <sc><i>KIT</i></sc> locus may predispose to melanoma. Pigment Cell and Melanoma Research, 2013, 26, 88-96.	3.3	5
189	No Modulation of Circulating Natural Killer Cell and Natural Killer Receptor Bearing Memory T Cell Subsets in Patients with Atopic Dermatitis. Journal of Investigative Dermatology, 2000, 115, 1160-1162.	0.7	4
190	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2021, 141, 193-197.e2.	0.7	4
191	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. Blood, 2021, 138, 790-790.	1.4	4
192	Regulation of the human allogeneic proliferative response in vitro. Immunogenetics, 1981, 14, 107-116.	2.4	3
193	Human T lymphocyte clones with killer or natural killer activity. Journal of Immunological Methods, 1986, 90, 215-219.	1.4	3
194	Rearranging sequence located in the intron of the human T cell receptor Î³ chain gene constant region. European Journal of Immunology, 1989, 19, 637-642.	2.9	3
195	Identification of a novel functional 85-kD glycoprotein restricted to long-term dividing human lymphocytic lines. Human Immunology, 1993, 37, 31-38.	2.4	3
196	CD antigens 2001. European Journal of Immunology, 2001, 31, 2841-2847.	2.9	3
197	CD antigens 2001. International Immunology, 2001, 13, 1095-1098.	4.0	3
198	NKp46-Specific Expression on Skin-Resident CD4 + Lymphocytes in Mycosis Fungoides and SÅ©zary Syndrome. Journal of Investigative Dermatology, 2014, 134, 574-578.	0.7	3

#	ARTICLE	IF	CITATIONS
199	PAK1-Dependent Antitumor Effect of AAC-11â€Derived Peptides on SÄ©zary Syndrome Malignant CD4+ T Lymphocytes. Journal of Investigative Dermatology, 2021, 141, 2261-2271.e5.	0.7	3
200	Functional characterization of an IL-7â€dependent CD4+CD8Î±Î± Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood, 2000, 96, 1056-1063.	1.4	3
201	Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing. European Journal of Cancer, 2021, 156, S3-S4.	2.8	3
202	857â€...Selective Treg depletion in solid tumors with ALD2510, a novel humanized CD25-specific, IL-2 sparing monoclonal antibody. , 2021, 9, A898-A898.		3
203	Differential reactivity of human lymphocytes allosensitized in vitro in hormonally defined medium or medium supplemented with plasma. Cellular Immunology, 1983, 81, 441-446.	3.0	2
204	In vitro allostimulation of peripheral blood mononuclear cells generates autologous reactive T lymphocytes: Analysis at the clonal level. Human Immunology, 1986, 17, 54-60.	2.4	2
205	Enhanced CD3 Monoclonal Antibody Induced Proliferation of Colonic Mucosal T Lymphocytes in Crohn's Disease Patients Free of Corticosteroid or Immunosuppressor Treatment. Clinical Immunology and Immunopathology, 1996, 79, 20-24.	2.0	2
206	MUC1/CD227 IMMUNOHISTOCHEMISTRY IN ROUTINE PRACTICE IS A USEFUL BIOMARKER IN BREAST CANCERS. Journal of Immunoassay and Immunochemistry, 2013, 34, 232-245.	1.1	2
207	CD160. , 2016, , 1-7.		2
208	Effect of expression of ICOS in cutaneous T-cell lymphoma and its targeting on killing of malignant cells.. Journal of Clinical Oncology, 2020, 38, e20040-e20040.	1.6	2
209	Identification of CD3 Associated T Cell Receptor as a Diagnostic Tool in T Cell Acute Lymphoblastic Lymphoma or Leukemia. Leukemia and Lymphoma, 1991, 4, 187-192.	1.3	1
210	Production and characterization of 22 monoclonal antibodies directed against S 20499, a new potent 5-HT1A chiral agonist: influence of the hapten structure on specificity and stereorecognition. Pharmaceutical Research, 1999, 16, 725-735.	3.5	1
211	T-cell: Section report. Cellular Immunology, 2005, 236, 3-5.	3.0	1
212	Authors' Reply. American Journal of Pathology, 2015, 185, 1168.	3.8	1
213	Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage. Experimental Dermatology, 2016, 25, 906-909.	2.9	1
214	Increased CD8+CD28- circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis. Journal of the American Academy of Dermatology, 2019, 85, 755-758.	1.2	1
215	Molecular and Functional Characterization of Human T-Cell Clones Expressing TCR-Î³Î³ Antigen Receptor. , 1989, , 554-554.		1
216	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. European Journal of Cancer, 2021, 156, S23-S24.	2.8	1

#	ARTICLE	IF	CITATIONS
217	Interleukin 17 in the tumor microenvironment: A potent target for anticancer immunotherapy?. Journal of Clinical Oncology, 2017, 35, 115-115.	1.6	1
218	CD4 cytotoxic T lymphocyte differentiation. Biochimie, 1988, 70, 937-941.	2.6	0
219	Detection of a T cell receptor $\hat{\nu}$ chain with an anti-TCR $\hat{\nu}$ chain serum. Clinical Immunology and Immunopathology, 1990, 55, 56-66.	2.0	0
220	Modulation of allogenic reaction by ticlopidine treatment. International Journal of Immunopharmacology, 1991, 13, 101-105.	1.1	0
221	SC3 monoclonal antibody defines a novel specific human B-cell surface antigen differentially expressed on B-cell leukaemias and lymphomas and involved in the proliferation of normal and malignant B lymphocytes. Cellular Immunology, 2005, 236, 92-100.	3.0	0
222	Revisiting blood classification in Mycosis Fungoides and S $\hat{\nu}$ zary syndrome with the KIR3DL2 marker. European Journal of Cancer, 2018, 101, S10-S11.	2.8	0
223	KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia (ATLL). European Journal of Cancer, 2018, 101, S7-S8.	2.8	0
224	Cutaneous T-cell lymphoma cells release proapoptotic Fas ligand in lysosomal secretory vesicles. European Journal of Cancer, 2019, 119, S17.	2.8	0
225	671 Study of the molecular and functional effects of wound dressings on human dermal fibroblasts. Journal of Investigative Dermatology, 2019, 139, S330.	0.7	0
226	Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes. Journal of Immunology, 2019, 202, 2057-2068.	0.8	0
227	664 Biological activities of traditional medicinal herbs on skin cells. Journal of Investigative Dermatology, 2019, 139, S329.	0.7	0
228	Secretomic and proteomic analysis of cutaneous T cell lymphoma-associated fibroblasts. European Journal of Cancer, 2021, 156, S5.	2.8	0
229	Anti-tumor effect of anti-apoptosis clone 11 protein-derived peptides on S $\hat{\nu}$ zary syndrome malignant CD4+ T lymphocytes. European Journal of Cancer, 2021, 156, S14.	2.8	0
230	Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and S $\hat{\nu}$ zary syndrome with the KIR3DL2 marker. European Journal of Cancer, 2021, 156, S6-S7.	2.8	0
231	Functional Role of CD101 on Skin Dendritic Cells. Advances in Experimental Medicine and Biology, 1997, 417, 227-232.	1.6	0
232	Abstract 1602: Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance. , 2017, , .		0
233	CD160. , 2018, , 846-852.		0
234	Chimerized Anti-ICOS 314.8 Monoclonal Antibodies Inhibit Tumor Cells and Regulatory T Cells in Patients with S $\hat{\nu}$ zary Syndrome. Blood, 2021, 138, 2260-2260.	1.4	0